SCHEMBL6687848

SCHEMBL6687848

CCC1SC(=O)N(Cc2ccc(NC(=O)c3ccno3)cc2)N=C1c1ccc(OC)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 13/20 0.45
PDE4A P27815 8/20 0.45
PDE4B Q07343 8/20 0.45
PDE4C Q08493 8/20 0.45
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
HSD17B10 Q99714 2/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 2/20 0.40
MAPK1 P28482 1/20 0.40
POLB P06746 1/20 0.40
TP53 P04637 2/20 0.40
TSHR P16473 1/20 0.40
XBP1 P17861 1/20 0.40
PPARG P37231 1/20 0.40
NCOA2 Q15596 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6689243 0.95 PDE4D (0.41) PDE4DPDE4APDE4BPDE4CKDM4E
SCHEMBL6685632 0.95 PDE4D (0.41) PDE4DPDE4APDE4BPDE4CKDM4E
SCHEMBL6684440 0.95 PDE4D (0.41) PDE4DPDE4APDE4BPDE4CKDM4E
SCHEMBL6685954 0.95 PDE4D (0.41) PDE4DPDE4APDE4BPDE4CKDM4E
SCHEMBL6690966 0.94 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CKDM4E
SCHEMBL6687573 0.94 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CKDM4E
SCHEMBL6689246 0.94 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CKDM4E
SCHEMBL6684080 0.94 PDE4D (0.40) PDE4DPDE4APDE4BPDE4CKDM4E
SCHEMBL6687566 0.94 MEN1 (0.39) PDE4DPDE4APDE4BPDE4CMAPT
SCHEMBL6687815 0.93 PDE4A (0.48) PDE4DPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040235845-A1 Use of phosphodiesterase iv inhibitors MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2004-11-25 US disclosed
EP-1435958-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GmbH (DE) 2004-07-14 EP disclosed
WO-2003032993-A1 USE OF PHOSPHORODIESTERASE IV INHIBITORS MERCK PATENT GMBH (DE) 2003-04-24 WO disclosed
EP-0763534-B1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GMBH (DE) 2003-02-26 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
EP-0763534-A1 Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors MERCK PATENT GmbH (DE) 1997-03-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235845-A1 Use of phosphodiesterase iv inhibitors PDE4A, PDE3A, PDE3B PDE4D 12/4885PDE4A 1/4885PDE4B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.